Pay in 4 interest-free payments of $5.22 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
The third retatrutide target
In the REDEFINE 1 clinical trial, patients treated with the combination achieved a mean weight loss of 22.7% at 68 weeks, and more than 40% of participants achieved at least a 25% reduction in body weight
Research from Russia and Eastern Europe, where DSIP has been studied more extensively than in the United States, has suggested the peptide may reduce withdrawal symptom severity and improve outcomes in opioid detoxification protocols
Third-party testing by independent laboratories provides an additional layer of verification
US$ 25.91
US$ 23.37
US$ 25.86
US$ 27.96
US$ 28.12
